Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Sep;10(3):892-901.
doi: 10.1177/23969873251315636. Epub 2025 Feb 5.

C-reactive protein expression in acute ischemic stroke blood clots: Implications for etiology

Affiliations
Multicenter Study

C-reactive protein expression in acute ischemic stroke blood clots: Implications for etiology

Wenyi Liu et al. Eur Stroke J. 2025 Sep.

Abstract

Introduction: C-reactive protein (CRP) is a prototypic inflammation marker, with elevated levels associated with an increased risk of cerebrovascular events. To determine whether CRP could be a useful biomarker of stroke etiology, we investigated CRP expression in acute ischemic stroke (AIS) clots from large-artery atherosclerosis (LAA), cardio-embolism (CE) and cryptogenic (Crypt) subtypes.

Patients and methods: We analysed clot samples from AIS patients (LAA, CE, Crypt; n = 50 each), collected across five stroke centres in France, Serbia, Spain, and Japan between February 2021 and February 2024, as part of the prospective Clotbase International Registry of 460 patients who underwent mechanical thrombectomy. Clot components were assessed using Martius Scarlet Blue staining. CRP expression was examined using immunohistochemistry and its co-localisation with clot components was detected using immunofluorescence. Clinical parameters were compared across etiologies.

Results: CRP expression varied significantly among clots. Most clots (65%) had minimal (⩽1%) CRP and 35% showed substantial (>1%) CRP. CE group had significantly more clots with substantial CRP than LAA and Crypt (48% vs 30% and 26%; p = 0.048). Clots with substantial CRP contained more fibrin (28.9%) than those with low CRP (20.6%; p = 0.005). Confocal microscopy showed CRP co-localised with fibrin and white blood cells (WBCs).

Discussion and conclusion: Significantly more AIS clots of CE expressed substantial CRP compared to those of LAA and Crypt, suggesting CE strokes may be more strongly linked to inflammation. Clots with substantial CRP expression displayed significantly more fibrin compared to those with minimal CRP expression, suggesting a potential association between inflammation and fibrin-rich clots. Further study of the relationship between CRP, fibrin and WBCs in clots may improve our understanding of the processes of thrombo-inflammation.

Keywords: Stroke; TOAST classification; etiology; inflammation.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Graphical abstract
Graphical abstract
Figure 1.
Figure 1.
Heterogeneity in CRP expression across clot samples. Representative IHC staining images of samples with minimal CRP expression (b) and samples with substantial CRP expression (d), along with their corresponding MSB staining images (a and c). Scale bar: 2 mm. Distribution of samples ranked by CRP quantitative levels from low to high (e). The green line represents the 1% CRP expression cut-off threshold (between samples 98 and 99).

References

    1. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol 2021; 20: 795–820. - PMC - PubMed
    1. Ajoolabady A, Wang S, Kroemer G, et al. Targeting autophagy in ischemic stroke: from molecular mechanisms to clinical therapeutics. Pharmacol Ther 2021; 225: 107848. - PMC - PubMed
    1. Zietz A, Gorey S, Kelly PJ, et al. Targeting inflammation to reduce recurrent stroke. Int J Stroke 2024; 19: 379–387. - PMC - PubMed
    1. Rizo-Téllez SA, Sekheri M, Filep JG. C-reactive protein: a target for therapy to reduce inflammation. Front Immunol 2023; 14: 1237729. - PMC - PubMed
    1. Sorgun MH, Kuzu M, Ozer IS, et al. Risk factors, biomarkers, etiology, outcome and prognosis of ischemic stroke in cancer patients. Asian Pac J Cancer Prev 2018; 19: 649–653. - PMC - PubMed

Publication types